Home    Back

Fluvastatin    (DrugBank: Fluvastatin)

3 diseases
IDDisease name (Link within this page)Number of trials
79Homozygous familial hypercholesterolemia1
218Alport syndrome1
222Primary nephrotic syndrome1

79. Homozygous familial hypercholesterolemia    [ 128 clinical trials,   105 drugs,   (DrugBank: 29 drugs),   8 drug target genes,   15 drug target pathways]
Searched query = "Homozygous familial hypercholesterolemia"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
1 / 128 trial found
No.TrialIDDate_
enrollment		Date_
registration		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
1NCT03510715
(ClinicalTrials.gov)		August 31, 201818/4/2018An Efficacy and Safety Study of Alirocumab in Children and Adolescents With Homozygous Familial HypercholesterolemiaAn Open-Label Study to Evaluate the Efficacy and Safety of Alirocumab in Children and Adolescents With Homozygous Familial HypercholesterolemiaHypercholesterolemiaDrug: Alirocumab SAR236553 (REGN727);Drug: Rosuvastatin;Drug: Ezetimibe;Drug: Cholestyramine;Drug: Nicotinic acid;Drug: Fenofibrate;Drug: Omega-3 fatty acids;Drug: Atorvastatin;Drug: Simvastatin;Drug: Fluvastatin;Drug: Pravastatin;Drug: LovastatinSanofiRegeneron PharmaceuticalsCompleted8 Years17 YearsAll18Phase 3Brazil;Canada;Denmark;Mexico;Netherlands;Russian Federation;Slovenia;Spain;Taiwan;Turkey;Austria;France;Italy;Norway;United States

218. Alport syndrome    [ 16 clinical trials,   24 drugs,   (DrugBank: 11 drugs),   5 drug target genes,   27 drug target pathways]
Searched query = "Alport syndrome"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
1 / 16 trial found
No.TrialIDDate_
enrollment		Date_
registration		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
1NCT00309257
(ClinicalTrials.gov)		January 200430/3/2006Effects of an Intensified Treatment With ACE-I,ATA II and Statins in Alport SyndromeEffects of an Intensified Treatment With ACE-inhibitors, Angiotensin II Receptor Antagonists and Statins in Alport SyndromeAlport SyndromeDrug: ACE I, ATA II and Statins;Drug: Benazepril, Valsartan and FluvastatinMario Negri Institute for Pharmacological ResearchNULLCompleted15 Years70 YearsBoth9Phase 2Italy

222. Primary nephrotic syndrome    [ 234 clinical trials,   241 drugs,   (DrugBank: 78 drugs),   59 drug target genes,   185 drug target pathways]
Searched query = "Primary nephrotic syndrome", "Minimal change nephrotic syndrome", "MCNS", "Membranous nephropathy", "Focal segmental glomerulosclerosis", "FSGS", "Membranoproliferative glomerulonephritis", "MPGN"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
1 / 234 trial found
No.TrialIDDate_
enrollment		Date_
registration		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
1ChiCTR-TQR-12002602
2009-10-092012-10-16The Effects of an Combinedative Treatment of with Prednisone plus and Fluvastatin on the Levels of Cholesterol and Bilirubin in the Patients with Minimal Change NephropathyThe Effects of an Combinedative Treatment of with Prednisone plus and Fluvastatin on the Levels of Cholesterol and Bilirubin in the Patients with Minimal Change Nephropathy Minimal change nephrotic syndrome in childrenTreatment:prednisone 1~2 mg/kg/day+Fluvastatin Sodium Capsule;Control:prednisone 1~2 mg/kg/day;Treatment center of kidney disease, 281th hospital of PLANULLCompleted412BothTreatment:30;Control:30;I (Phase 1 study)China